WSC 2025 | The use of GFAP to differentiate between ICH and AIS in the pre-hospital setting
Love-Preet Kalra, MD, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany, discusses the role of glial fibrillary acidic protein (GFAP) as a potential biomarker for intracerebral hemorrhage (ICH). Dr Kalra explains that GFAP is released into the bloodstream when brain tissue is damaged, and can be used to differentiate between ICH and acute ischemic stroke (AIS). This interview took place at the 17th World Stroke Congress (WSC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
GFAP, also called glial fibrillary acidic protein, is a brain-specific protein which is highly prevalent in astrocytes and is released whenever there is damage happening to brain tissue. So in ICH, there is a more rapid release of GFAP into bloodstream due to the rapidly expanding hematoma. And in ischemic stroke, there is a more gradual necrosis. So it was proven that within the six hours, there is a higher level of GFAP in those patients affected by ICH compared to patients with ischemic stroke...
GFAP, also called glial fibrillary acidic protein, is a brain-specific protein which is highly prevalent in astrocytes and is released whenever there is damage happening to brain tissue. So in ICH, there is a more rapid release of GFAP into bloodstream due to the rapidly expanding hematoma. And in ischemic stroke, there is a more gradual necrosis. So it was proven that within the six hours, there is a higher level of GFAP in those patients affected by ICH compared to patients with ischemic stroke. So we are looking forward to make GFAP the ICH marker which can be used in the pre-hospital setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
